RESUMEN
Systemic sclerosis (SSc) is a progressive, multiorgan disease with limited treatment options. Although a recent proof-of-concept study using romilkimab or SAR156597, a bispecific IL-4/IL-13 antibody, suggests a direct role of these cytokines in the pathophysiology of SSc, their contributions to the balance between inflammation and fibrosis are unclear. Here, we determine the roles of type 2 inflammation in fibrogenesis using FRA2-Tg (Fos-related antigen 2-overexpressing transgenic) mice, which develop spontaneous, age-dependent progressive lung fibrosis. We defined the molecular signatures of inflammation and fibrosis at three key stages in disease progression, corresponding to preonset, inflammatory dominant, and fibrosis dominant biology, and revealed an early increase in cytokine-cytokine receptor interactions and antigen-processing and presentation pathways followed by enhanced Th2- and M2 macrophage-driven type 2 responses. This type 2 inflammation progressed to extensive fibrotic pathology by 14-18 weeks of age, with these gene signatures overlapping significantly with those seen in the lungs of patients with SSc with interstitial lung disease (ILD). These changes were also evident in the histopathology, which showed perivascular and peribronchiolar inflammation with prominent eosinophilia and accumulation of profibrotic M2-like macrophages followed by rapid progression to fibrosis with thickened alveolar walls with multifocal fibrotic bands and signs of interstitial pneumonia. Critically, treatment with a bispecific antibody targeting IL-4 and IL-13 during the inflammatory phase abrogated the Th2 and M2 responses and led to near-complete abrogation of lung fibrosis. These data recapitulate important features of fibrotic progression in the lungs of patients with SSc-ILD and enhance our understanding of the progressive pathobiology of SSc. This study also further establishes FRA2-Tg mice as a valuable tool for testing future therapeutic agents in SSc-ILD.
Asunto(s)
Enfermedades Pulmonares Intersticiales , Fibrosis Pulmonar , Esclerodermia Sistémica , Humanos , Ratones , Animales , Fibrosis Pulmonar/patología , Interleucina-13 , Interleucina-4 , Enfermedades Pulmonares Intersticiales/patología , Fibrosis , Pulmón/patología , Inflamación/patología , Ratones Transgénicos , CitocinasRESUMEN
Treatment for fibrosis represents a critical unmet need, because fibrosis is the leading cause of death in industrialized countries, and there is no effective therapy to counteract the fibrotic process. The development of fibrosis relates to the interplay between vessel injury, immune cell activation, and fibroblast stimulation, which can occur in various tissues. Immunotherapies have provided a breakthrough in the treatment of immune diseases. The glycoprotein OX40-OX40 ligand (OX40L) axis offers the advantage of a targeted approach to costimulatory signals with limited impact on the whole immune response. Using systemic sclerosis (SSc) as a prototypic disease, we report compelling evidence that blockade of OX40L is a promising strategy for the treatment of inflammation-driven fibrosis. OX40L is overexpressed in the fibrotic skin and serum of patients with SSc, particularly in patients with diffuse cutaneous forms. Soluble OX40L was identified as a promising serum biomarker to predict the worsening of lung and skin fibrosis, highlighting the role of this pathway in fibrosis. In vivo, OX40L blockade prevents inflammation-driven skin, lung, and vessel fibrosis and induces the regression of established dermal fibrosis in different complementary mouse models. OX40L exerts potent profibrotic effects by promoting the infiltration of inflammatory cells into lesional tissues and therefore the release of proinflammatory mediators, thereafter leading to fibroblast activation.
Asunto(s)
Ligando OX40/antagonistas & inhibidores , Ligando OX40/sangre , Fibrosis Pulmonar/prevención & control , Esclerodermia Sistémica/sangre , Piel/patología , Animales , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Biomarcadores/sangre , Bleomicina , Estudios de Casos y Controles , Células Cultivadas , Evaluación Preclínica de Medicamentos , Fibrosis , Antígeno 2 Relacionado con Fos/genética , Humanos , Hipertensión Pulmonar/prevención & control , Ratones Endogámicos C57BL , Ratones Transgénicos , Persona de Mediana Edad , Terapia Molecular Dirigida , Fibrosis Pulmonar/genética , Esclerodermia Sistémica/tratamiento farmacológico , Piel/metabolismo , Factor de Transcripción AP-1/metabolismoRESUMEN
The purpose of the current article is to encourage discussion among stakeholders about the viability and benefits of predoctoral prescriptive authority (RxP) training. The existing APA model curriculum for RxP training requires that such training is postdoctoral. However, predoctoral models are potentially viable and offer several distinct advantages: reducing the time and financial costs of training, attracting more applicants with a biopsychosocial orientation, and, as more individuals complete this training, enlarging the constituency for state prescriptive authority initiatives. Several possible predoctoral model curricula including the incorporation of a postdoctoral master's degree in clinical psychopharmacology are described within existing APA PhD program requirements, with suggested accommodations for PsyD programs. These are offered as alternatives to, rather than as replacements for, postdoctoral training for RxP.
Asunto(s)
Medicamentos bajo Prescripción/uso terapéutico , Psicología Clínica/educación , Curriculum , Humanos , Modelos Educacionales , Psicotrópicos/uso terapéutico , Sociedades Médicas , Estados UnidosRESUMEN
OBJECTIVE: To elucidate the role of gene candidates involved in pulmonary hypertension (PH) associated with systemic sclerosis (SSc). METHODS: Gene candidates were identified through microarray experiments performed on Affymetrix GeneChip Human Exon 1.0 ST arrays in endothelial progenitor cell (EPC)-derived endothelial cells (ECs) obtained from patients with SSc-associated PH, patients with SSc without PH, and healthy control subjects. Expression of identified gene candidates was assessed by quantitative sandwich enzyme-linked immunosorbent assay in the serum, and by immunohistochemistry in lesional lung tissue. The functional importance of the identified gene candidates was then evaluated in fos-related antigen 2-transgenic (Fra-2-Tg) mice that spontaneously develop SSc-like features associated with an intense pulmonary vascular remodeling. RESULTS: Microarray experiments revealed that the matrix metalloproteinase 10 (MMP-10) gene was the top up-regulated gene in SSc-associated PH EPC-derived ECs. Circulating serum proMMP10 concentrations were markedly increased in patients with SSc-associated PH compared to SSc patients without PH and healthy controls. Consistent with these observations, a strong MMP10 staining of the thickened wall of distal pulmonary arteries was found both in the lungs of patients with SSc-associated PH and in the lungs of Fra-2-Tg mice. Daily treatment of Fra-2-Tg mice with neutralizing anti-MMP10 antibodies did not significantly affect the development and severity of pulmonary fibrosis, but did reverse established PH and markedly reduced pulmonary vascular remodeling by reducing cell proliferation, cell survival, and the platelet-derived growth factor signaling axis. CONCLUSION: Gene expression profiling of EPC-derived ECs identified MMP10 as a novel candidate gene in SSc-associated PH. MMP10 is overexpressed in the serum and pulmonary arteries of patients with SSc-associated PH, and its blockade alleviates PH in the Fra-2-Tg mouse model. MMP10 appears to be a prospective treatment target for this devastating disorder.
Asunto(s)
Células Endoteliales/metabolismo , Hipertensión Pulmonar/genética , Metaloproteinasa 10 de la Matriz/genética , Arteria Pulmonar/metabolismo , Fibrosis Pulmonar/genética , Esclerodermia Sistémica/genética , Adulto , Anciano , Animales , Anticuerpos Neutralizantes/farmacología , Estudios de Casos y Controles , Proliferación Celular/efectos de los fármacos , Supervivencia Celular , Modelos Animales de Enfermedad , Células Progenitoras Endoteliales , Ensayo de Inmunoadsorción Enzimática , Femenino , Antígeno 2 Relacionado con Fos/genética , Humanos , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Masculino , Metaloproteinasa 10 de la Matriz/inmunología , Metaloproteinasa 10 de la Matriz/metabolismo , Ratones , Ratones Transgénicos , Análisis por Micromatrices , Persona de Mediana Edad , Factor de Crecimiento Derivado de Plaquetas/efectos de los fármacos , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Fibrosis Pulmonar/etiología , Fibrosis Pulmonar/metabolismo , Esclerodermia Sistémica/complicaciones , Esclerodermia Sistémica/metabolismo , Transducción de Señal , Remodelación Vascular/efectos de los fármacosRESUMEN
Ambient ozone has been linked to the worsening of symptoms of patients with obstructive diseases such as chronic obstructive pulmonary disease (COPD) and asthma. We investigated the role of cathepsin S on ozone-induced airway hyperresponsiveness (AHR) and inflammation, using the selective cathepsin S inhibitor, Compound A. Balb/c mice were exposed to ozone at a concentration of 3 ppm or air for 3 h, following administration by gavage of Compound A or vehicle. Bronchoalveolar lavage (BAL) was performed 3 h and 20-24 h following exposure, AHR was measured at 20-24 h only. Ozone exposure, compared to air exposure increased BAL cathepsin S levels, AHR and BAL inflammatory cells. Compound A (30 mg kg(-1) p.o.) dosing compared to vehicle dosing inhibited ozone-induced AHR (-logPC100 vehicle: -0.70+/-0.12, n=8 vs. cathepsin S inhibitor: -1.30+/-0.06, P<0.001, n=8) at 20-24 h and BAL neutrophilia at 3 h and 20-24 h (P<0.05, n=6). Ozone exposure increased levels of BAL cytokines IL-6, TNF-alpha and IFN-gamma. Compound A reduced IL-6 at 3 h and 20-24 h (P<0.05, n=5) and TNF-alpha, at 20-24 h (P<0.05, n=6). These data indicate an important role for cathepsin S in the regulation of ozone-induced AHR and neutrophil cell recruitment and suggest that cathepsin S may be a target in the treatment of oxidative stress-induced AHR and inflammation.
Asunto(s)
Hiperreactividad Bronquial/fisiopatología , Catepsinas/metabolismo , Inflamación/fisiopatología , Ozono/toxicidad , Contaminantes Atmosféricos/toxicidad , Animales , Hiperreactividad Bronquial/inducido químicamente , Lavado Broncoalveolar , Catepsinas/antagonistas & inhibidores , Sistemas de Liberación de Medicamentos , Inflamación/inducido químicamente , Interferón gamma/efectos de los fármacos , Interferón gamma/metabolismo , Interleucina-6/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Infiltración Neutrófila/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Factores de Tiempo , Factor de Necrosis Tumoral alfa/efectos de los fármacos , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
UNLABELLED: Aberrant expression of cyclooxygenase-2 in hepatocellular carcinoma was described in Asia. Using immunohistochemistry, we studied the expression of cyclooxygenase-2 in hepatocellular carcinoma, chronic hepatitis, and cirrhosis in a US institution. A staining score of 0-5 representing the sum of an intensity score and a distribution score was used. The mean scores were 2.2+/-1.60 for chronic hepatitis, 4.37+/-1.15 for cirrhosis, and 4.76+/-0.54 for hepatocellular carcinoma. We found a significant difference in mean staining scores between chronic hepatitis and cirrhosis (p < 0.0001), as well as between chronic hepatitis and hepatocellular carcinoma (p < 0.0001). Fibrosis correlated with cyclooxygenase-2 staining score (r=0.65). IN CONCLUSION: (1) Cyclooxygenase-2 expression is higher in cirrhosis and hepatocellular carcinoma when compared to chronic hepatitis. (2) Cyclooxygenase-2 expression correlates with the stage of fibrosis. (3) These results imply that in chronic hepatitis and possibly in cirrhosis, hepatocarcinogenesis may be a cyclooxygenase-2 dependent mechanism.
Asunto(s)
Carcinoma Hepatocelular/metabolismo , Ciclooxigenasa 2/metabolismo , Hepatitis Crónica/metabolismo , Cirrosis Hepática/metabolismo , Neoplasias Hepáticas/metabolismo , Adulto , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Estados UnidosRESUMEN
Attention deficit hyperactivity disorder (ADHD) has been long recognized and well established in children, but its continuation into adulthood has only recently been supported by the research. ADHD symptoms and concerns typically appear differently in adults, but treatment options, conceptually at least, are similar to those used for children who have ADHD. This article introduces the issue of Journal of Clinical Psychology: In Session devoted to ADHD in teens and adults. It presents the prevalence and manifestations of the disorder and then reviews the subsequent articles on the comorbidity, evaluation, education, psychopharmacology, and psychosocial treatments of ADHD for teens and adults. The issue concludes with an article on neurobiofeedback, a relatively new treatment option.